<p>在地緣政治緊張局勢加劇、通脹擔憂持續以及油價波動的背景下，全球市場經歷了顯著波動，美國股指本週收盤下跌。隨着主要經濟體的中央銀行在這些不確定性中發出謹慎信號並維持利率，投資者越來越關注能夠有效應對這些挑戰環境的高增長機會，尤其是在科技等領域。</p>
<h3>全球十大高增長科技公司</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hacksaw</td>
<td>24.17%</td>
<td>25.33%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Giant Network Group</td>
<td>36.46%</td>
<td>42.98%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Zhongji Innolight</td>
<td>32.97%</td>
<td>35.32%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi TechnologyLtd</td>
<td>24.24%</td>
<td>32.49%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>28.13%</td>
<td>38.63%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>26.92%</td>
<td>36.01%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CD Projekt</td>
<td>33.42%</td>
<td>28.82%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Co-Tech Development</td>
<td>34.37%</td>
<td>65.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Suzhou Dongshan Precision Manufacturing</td>
<td>36.66%</td>
<td>84.97%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>64.21%</td>
<td>83.56%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們全球高增長科技和人工智能股票篩選器中的 205 只股票的完整列表。</p>
<p>我們將從篩選結果中選取一些進行分析。</p>
<h2>ALTEOGEN (KOSDAQ:A196170)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> ALTEOGEN Inc.是一家生物技術公司，專注於開發長效生物更好藥物、專有抗體藥物偶聯物和抗體生物仿製藥，市值為 191.8 億韓元。</p>
<p><strong>運營：</strong> 該公司主要通過其生物技術部門產生收入，金額為 2021.8 億韓元。它專注於開發創新的生物製藥產品，如長效生物更好藥物和抗體藥物偶聯物。</p>
<p>Alteogen 展現了令人印象深刻的財務和戰略增長，年化收入增長達到 65.5%，盈利增長預測為 80.2%。該公司對創新的承諾通過其研發支出得以體現，這對維持其在競爭激烈的生物技術領域的快速擴張至關重要。最近，Alteogen 與 Biogen 簽署了一項有利可圖的協議，開發使用其專有 Hybrozyme 技術的皮下製劑，預計將帶來超過 5.49 億美元的里程碑付款以及銷售提成。這一合作不僅提升了 Alteogen 的財務前景，還鞏固了其在生物製藥領域的地位，承諾持續增長和行業相關性。</p>
<ul>
<li>點擊這裏深入瞭解 ALTEOGEN 的完整分析健康報告。</li>
<li>在我們的歷史部分查看 ALTEOGEN 的歷史數據，以跟蹤其表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d80fbba0-7549-495e-94ef-6fdcdebf6ead/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d80fbba0-7549-495e-94ef-6fdcdebf6ead/chart/earnings-and-revenue-growth"/></p>
<p>KOSDAQ:A196170 截至 2026 年 3 月的盈利和收入增長</p>
<h2>Celestica (TSX:CLS)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Celestica Inc.及其子公司在亞洲、北美及全球提供供應鏈解決方案，市值為 476.7 億加元。</p>
<p><strong>運營：</strong> Celestica 通過其先進技術解決方案（ATS）和連接與雲解決方案（CCS）部門產生收入，其中 CCS 貢獻的份額更大，達到 91.9 億美元，而 ATS 為 32 億美元。</p>
<p>Celestica 最近展現了強勁的財務表現，過去一年盈利增長顯著，達到 94.5%，遠超電子行業 17.7% 的增長。這一增長得益於其向高需求領域（如人工智能）的戰略轉型，通過與 AMD 的合作開發先進的網絡交換機以支持 AI 平台。此外，Celestica 在研發方面的承諾通過其在該領域的重大投資得以體現，符合行業向增強技術能力和創新的趨勢。該公司還積極管理資本配置，反映在 2025 年 10 月至 2026 年 2 月回購價值 5570 萬美元的股票上，顯示出對其財務健康和未來前景的信心。</p>
<ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解 Celestica 的動態。</li>
<li>查看 Celestica 的過去表現報告，以瞭解其過去的表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6b48679f-be15-4048-9b13-af27391c8b36/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6b48679f-be15-4048-9b13-af27391c8b36/chart/revenue-and-expenses-breakdown"/></p>
<p>TSX:CLS 截至 2026 年 3 月的收入和支出細分</p>
<h2>Zhen Ding Technology Holding (TWSE:4958)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Zhen Ding Technology Holding Limited 及其子公司涉及印刷電路板產品的設計、開發、製造和銷售，市場覆蓋美國、中國大陸、台灣和新加坡，市值為 2220.5 億新台幣。</p>
<p><strong>運營：</strong> 該公司專注於印刷電路板（PCB）的設計、開發、製造和銷售，從該部門產生 1825.2 億新台幣的收入。</p>
<p>儘管 Zhen Ding Technology Holding 最近淨收入從 91.8 億新台幣下降至 67.9 億新台幣，但預計年盈利增長為 41.2%，超過台灣市場平均水平 21.4%。這一強勁的預測得益於其積極的研發投資策略，符合行業向先進技術解決方案的轉變。該公司在三月份參與多場高端會議，凸顯其在區域技術討論中的積極角色，增強了其行業影響力，並可能提升未來表現。</p>
<ul>
<li>點擊探索我們在振鼎科技控股健康報告中的詳細發現。</li>
<li>瞭解振鼎科技控股的歷史表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5c57781d-e5a0-4308-bb9d-248b5400a9e1/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5c57781d-e5a0-4308-bb9d-248b5400a9e1/chart/earnings-and-revenue-growth"/></p>
<p>TWSE:4958 截至 2026 年 3 月的收益和收入增長</p>
<h2>總結</h2>
<ul>
<li>點擊這裏更詳細地查看我們全球高增長科技和人工智能股票的 205 家公司名單。</li>
<li>這些公司中有哪一些是你資產組合的一部分嗎？利用 Simply Wall St 的投資組合分析功能，全面瞭解它們的表現。</li>
<li>通過 Simply Wall St 解鎖知情投資的力量，這是你在全球股市中導航的免費指南。</li>
</ul>
<h2>尋找新視角？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實你的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容為一般性信息。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮你的目標或財務狀況。我們旨在為你提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<h3><strong>新功能：</strong> AI 股票篩選器和警報</h3>
<p>我們的新 AI 股票篩選器每天掃描市場以發現機會。</p>
<p>• 分紅強勁的公司（收益率 3% 以上）</p>
<p>• 內部人士買入的被低估小型股</p>
<p>• 高增長科技和人工智能公司</p>
<p>或者從 50 多個指標中構建你自己的篩選器。</p>
<p>立即免費探索</p>

科創醫藥ETF工銀

平安中證醫療創新ETF

方正富邦中證醫藥及醫療器械創新ETF

<p>在地緣政治緊張和通貨膨脹的背景下，全球市場波動，美國股指下跌。投資者正關注高增長的科技股。值得注意的公司包括 Hacksaw、巨人網絡集團和 CARsgen Therapeutics，它們都顯示出令人印象深刻的收入和盈利增長。ALTEOGEN 和 Celestica 因其強勁的財務表現和戰略合作伙伴關係而受到關注，而震鼎科技則因儘管近期收入有所下降，但仍展現出良好的盈利增長潛力。報告強調了在應對當前市場挑戰中，創新和研發的重要性</p>

<p>Amidst a backdrop of heightened geopolitical tensions, persistent inflation concerns, and volatile oil prices, global markets have experienced significant fluctuations with U.S. equity indexes finishing lower for the week. As central banks across major economies signal caution and maintain interest rates amid these uncertainties, investors are increasingly focused on identifying high growth opportunities in sectors like technology that can navigate such challenging environments effectively.</p>
<div class="lb-trans"><p>在地緣政治緊張局勢加劇、通脹擔憂持續以及油價波動的背景下，全球市場經歷了顯著波動，美國股指本週收盤下跌。隨着主要經濟體的中央銀行在這些不確定性中發出謹慎信號並維持利率，投資者越來越關注能夠有效應對這些挑戰環境的高增長機會，尤其是在科技等領域。</p>
</div><h3>Top 10 High Growth Tech Companies Globally</h3>
<div class="lb-trans"><h3>全球十大高增長科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hacksaw</td>
<td>24.17%</td>
<td>25.33%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Giant Network Group</td>
<td>36.46%</td>
<td>42.98%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Zhongji Innolight</td>
<td>32.97%</td>
<td>35.32%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi TechnologyLtd</td>
<td>24.24%</td>
<td>32.49%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>28.13%</td>
<td>38.63%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>26.92%</td>
<td>36.01%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CD Projekt</td>
<td>33.42%</td>
<td>28.82%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Co-Tech Development</td>
<td>34.37%</td>
<td>65.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Suzhou Dongshan Precision Manufacturing</td>
<td>36.66%</td>
<td>84.97%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>64.21%</td>
<td>83.56%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hacksaw</td>
<td>24.17%</td>
<td>25.33%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Giant Network Group</td>
<td>36.46%</td>
<td>42.98%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Zhongji Innolight</td>
<td>32.97%</td>
<td>35.32%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi TechnologyLtd</td>
<td>24.24%</td>
<td>32.49%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>28.13%</td>
<td>38.63%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>26.92%</td>
<td>36.01%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CD Projekt</td>
<td>33.42%</td>
<td>28.82%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Co-Tech Development</td>
<td>34.37%</td>
<td>65.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Suzhou Dongshan Precision Manufacturing</td>
<td>36.66%</td>
<td>84.97%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>64.21%</td>
<td>83.56%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 205 stocks from our Global High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們全球高增長科技和人工智能股票篩選器中的 205 只股票的完整列表。</p>
</div><p>We'll examine a selection from our screener results.</p>
<div class="lb-trans"><p>我們將從篩選結果中選取一些進行分析。</p>
</div><h2>ALTEOGEN (KOSDAQ:A196170)</h2>
<div class="lb-trans"><h2>ALTEOGEN (KOSDAQ:A196170)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩19.18 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> ALTEOGEN Inc.是一家生物技術公司，專注於開發長效生物更好藥物、專有抗體藥物偶聯物和抗體生物仿製藥，市值為 191.8 億韓元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its biotechnology segment, amounting to ₩202.18 billion. It focuses on developing innovative biopharmaceutical products such as long-acting biobetters and antibody-drug conjugates.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過其生物技術部門產生收入，金額為 2021.8 億韓元。它專注於開發創新的生物製藥產品，如長效生物更好藥物和抗體藥物偶聯物。</p>
</div><p>Alteogen has demonstrated impressive financial and strategic growth, evidenced by its annualized revenue increase of 65.5% and earnings growth forecast at 80.2%. The company's commitment to innovation is highlighted by its R&amp;D expenses, crucial for sustaining its rapid expansion in the competitive biotech sector. Recently, Alteogen inked a lucrative deal with Biogen for the development of subcutaneous formulations using its proprietary Hybrozyme technology, potentially bringing in over $549 million in milestone payments plus royalties on sales. This partnership not only boosts Alteogen’s financial outlook but also solidifies its standing in biologics, promising sustained growth and industry relevance.</p>
<div class="lb-trans"><p>Alteogen 展現了令人印象深刻的財務和戰略增長，年化收入增長達到 65.5%，盈利增長預測為 80.2%。該公司對創新的承諾通過其研發支出得以體現，這對維持其在競爭激烈的生物技術領域的快速擴張至關重要。最近，Alteogen 與 Biogen 簽署了一項有利可圖的協議，開發使用其專有 Hybrozyme 技術的皮下製劑，預計將帶來超過 5.49 億美元的里程碑付款以及銷售提成。這一合作不僅提升了 Alteogen 的財務前景，還鞏固了其在生物製藥領域的地位，承諾持續增長和行業相關性。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of ALTEOGEN.</li>
<li>Explore historical data to track ALTEOGEN's performance over time in our Past section.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 ALTEOGEN 的完整分析健康報告。</li>
<li>在我們的歷史部分查看 ALTEOGEN 的歷史數據，以跟蹤其表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d80fbba0-7549-495e-94ef-6fdcdebf6ead/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/d80fbba0-7549-495e-94ef-6fdcdebf6ead/chart/earnings-and-revenue-growth"/></p>
<p>KOSDAQ:A196170 Earnings and Revenue Growth as at Mar 2026</p>
<div class="lb-trans"><p>KOSDAQ:A196170 截至 2026 年 3 月的盈利和收入增長</p>
</div><h2>Celestica (TSX:CLS)</h2>
<div class="lb-trans"><h2>Celestica (TSX:CLS)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Celestica Inc., along with its subsidiaries, offers supply chain solutions across Asia, North America, and globally, with a market capitalization of CA$47.67 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Celestica Inc.及其子公司在亞洲、北美及全球提供供應鏈解決方案，市值為 476.7 億加元。</p>
</div><p><strong>Operations:</strong> Celestica generates revenue through its Advanced Technology Solutions (ATS) and Connectivity &amp; Cloud Solutions (CCS) segments, with CCS contributing a larger share at $9.19 billion compared to ATS's $3.20 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> Celestica 通過其先進技術解決方案（ATS）和連接與雲解決方案（CCS）部門產生收入，其中 CCS 貢獻的份額更大，達到 91.9 億美元，而 ATS 為 32 億美元。</p>
</div><p>Celestica has recently demonstrated robust financial performance, with a notable 94.5% surge in earnings over the past year, significantly outpacing the electronics industry's growth of 17.7%. This growth is underpinned by a strategic pivot towards high-demand sectors like AI through partnerships, such as their recent collaboration with AMD to develop advanced networking switches for AI platforms. Furthermore, Celestica's commitment to R&amp;D is evident from its substantial investment in this area, aligning with industry trends towards enhanced technological capabilities and innovation. The company also actively manages its capital allocation, evidenced by the repurchase of shares worth $55.7 million from October 2025 to February 2026, reflecting confidence in its financial health and future prospects.</p>
<div class="lb-trans"><p>Celestica 最近展現了強勁的財務表現，過去一年盈利增長顯著，達到 94.5%，遠超電子行業 17.7% 的增長。這一增長得益於其向高需求領域（如人工智能）的戰略轉型，通過與 AMD 的合作開發先進的網絡交換機以支持 AI 平台。此外，Celestica 在研發方面的承諾通過其在該領域的重大投資得以體現，符合行業向增強技術能力和創新的趨勢。該公司還積極管理資本配置，反映在 2025 年 10 月至 2026 年 2 月回購價值 5570 萬美元的股票上，顯示出對其財務健康和未來前景的信心。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of Celestica.</li>
<li>Examine Celestica's past performance report to understand how it has performed in the past.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解 Celestica 的動態。</li>
<li>查看 Celestica 的過去表現報告，以瞭解其過去的表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6b48679f-be15-4048-9b13-af27391c8b36/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/6b48679f-be15-4048-9b13-af27391c8b36/chart/revenue-and-expenses-breakdown"/></p>
<p>TSX:CLS Revenue and Expenses Breakdown as at Mar 2026</p>
<div class="lb-trans"><p>TSX:CLS 截至 2026 年 3 月的收入和支出細分</p>
</div><h2>Zhen Ding Technology Holding (TWSE:4958)</h2>
<div class="lb-trans"><h2>Zhen Ding Technology Holding (TWSE:4958)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Zhen Ding Technology Holding Limited, along with its subsidiaries, is involved in the design, development, manufacture, and sale of printed circuit board products across various international markets including the United States, Mainland China, Taiwan, and Singapore with a market capitalization of NT$222.05 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Zhen Ding Technology Holding Limited 及其子公司涉及印刷電路板產品的設計、開發、製造和銷售，市場覆蓋美國、中國大陸、台灣和新加坡，市值為 2220.5 億新台幣。</p>
</div><p><strong>Operations:</strong> The company focuses on the design, development, manufacture, and sale of printed circuit boards (PCBs), generating NT$182.52 billion in revenue from this segment.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司專注於印刷電路板（PCB）的設計、開發、製造和銷售，從該部門產生 1825.2 億新台幣的收入。</p>
</div><p>Zhen Ding Technology Holding, despite a recent dip in net income from TWD 9.18 billion to TWD 6.79 billion, continues to show promise with an expected annual earnings growth of 41.2%, outpacing the Taiwan market's average of 21.4%. This robust projection is supported by their aggressive R&amp;D investment strategy, aligning with industry shifts towards advanced tech solutions. The company's participation in multiple high-profile conferences this March underscores its active role in shaping tech discussions regionally, enhancing its industry presence and potentially bolstering future performance.</p>
<div class="lb-trans"><p>儘管 Zhen Ding Technology Holding 最近淨收入從 91.8 億新台幣下降至 67.9 億新台幣，但預計年盈利增長為 41.2%，超過台灣市場平均水平 21.4%。這一強勁的預測得益於其積極的研發投資策略，符合行業向先進技術解決方案的轉變。該公司在三月份參與多場高端會議，凸顯其在區域技術討論中的積極角色，增強了其行業影響力，並可能提升未來表現。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Zhen Ding Technology Holding's health report.</li>
<li>Learn about Zhen Ding Technology Holding's historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們在振鼎科技控股健康報告中的詳細發現。</li>
<li>瞭解振鼎科技控股的歷史表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/5c57781d-e5a0-4308-bb9d-248b5400a9e1/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/5c57781d-e5a0-4308-bb9d-248b5400a9e1/chart/earnings-and-revenue-growth"/></p>
<p>TWSE:4958 Earnings and Revenue Growth as at Mar 2026</p>
<div class="lb-trans"><p>TWSE:4958 截至 2026 年 3 月的收益和收入增長</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>總結</h2>
</div><ul>
<li>Take a closer look at our Global High Growth Tech and AI Stocks list of 205 companies by clicking here.</li>
<li>Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.</li>
<li>Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏更詳細地查看我們全球高增長科技和人工智能股票的 205 家公司名單。</li>
<li>這些公司中有哪一些是你資產組合的一部分嗎？利用 Simply Wall St 的投資組合分析功能，全面瞭解它們的表現。</li>
<li>通過 Simply Wall St 解鎖知情投資的力量，這是你在全球股市中導航的免費指南。</li>
</ul>
</div><h2>Searching for a Fresh Perspective?</h2>
<div class="lb-trans"><h2>尋找新視角？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實你的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容為一般性信息。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮你的目標或財務狀況。我們旨在為你提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><h3><strong>New:</strong> AI Stock Screener &amp; Alerts</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> AI 股票篩選器和警報</h3>
</div><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p>
<div class="lb-trans"><p>我們的新 AI 股票篩選器每天掃描市場以發現機會。</p>
</div><p>• Dividend Powerhouses (3%+ Yield)</p>
<div class="lb-trans"><p>• 分紅強勁的公司（收益率 3% 以上）</p>
</div><p>• Undervalued Small Caps with Insider Buying</p>
<div class="lb-trans"><p>• 內部人士買入的被低估小型股</p>
</div><p>• High growth Tech and AI Companies</p>
<div class="lb-trans"><p>• 高增長科技和人工智能公司</p>
</div><p>Or build your own from over 50 metrics.</p>
<div class="lb-trans"><p>或者從 50 多個指標中構建你自己的篩選器。</p>
</div><p>Explore Now for Free</p>
<div class="lb-trans"><p>立即免費探索</p>
</div>

探索 2026 年 3 月的高增長科技股票